Welcome to our dedicated page for Allarity SEC filings (Ticker: ALLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Allarity Therapeutics Inc (ALLR) files regular reports with the SEC that document its clinical trial progress, financial position, and strategic developments as a clinical-stage biotechnology company. The company's 10-K annual reports and 10-Q quarterly filings provide detailed disclosures about its drug development pipeline, including trial designs, patient enrollment status, and regulatory interactions. These documents reveal how the company allocates resources across its oncology programs and partnerships, offering transparency into which therapeutic candidates receive priority investment.
For clinical-stage biotech companies like Allarity, SEC filings contain critical information about cash runway, research and development expenses, and licensing agreement terms that directly impact the company's ability to advance drug candidates toward regulatory approval. The 10-K and 10-Q reports include management's discussion of clinical trial results, regulatory feedback, and pipeline strategy that may not be fully detailed in press releases. Our AI-powered summaries highlight these key disclosures, saving hours of manual analysis.
Form 4 insider transaction filings reveal when executives and directors buy or sell ALLR shares, providing signals about insider confidence in the company's clinical programs. Material event 8-K filings announce significant developments such as licensing agreements, clinical trial initiations, regulatory designations, and partnership deals as they occur. DEF 14A proxy statements disclose executive compensation structures and board governance matters. Access real-time EDGAR filings with AI-generated explanations that clarify complex biotechnology disclosures, clinical trial accounting, and regulatory pathway discussions specific to Allarity's precision oncology focus.
Allarity Therapeutics (ALLR) filed its Q3 2025 report, highlighting a smaller quarterly net loss and stable liquidity. Net loss was $2.8 million for the quarter and $7.9 million year-to-date. Cash and cash equivalents were $16.9 million as of September 30, 2025, and management expects this to fund operations for at least the next 12 months.
Operating cash outflow was $11.6 million for the nine months. The company raised capital via an ATM program with $9.7 million net proceeds year-to-date and completed a private placement of 1,562,500 shares at $1.60 per share for roughly $2.5 million gross. Allarity also executed a share repurchase program, buying 2,600,763 shares for $2.706 million, with $2.294 million remaining authorized.
The FDA granted Fast Track designation to stenoparib for advanced ovarian cancer, supporting development interactions. The company reported a material weakness in internal controls related to accounting for the repurchase program and is implementing remediation. Shares outstanding were 16,111,461 as of September 30, 2025; 15,811,886 were reported outstanding as of November 13, 2025.
Jeremy R. Graff, President and Chief Development Officer of Allarity Therapeutics, Inc. (ALLR), reported transactions dated 09/30/2025. 39,494 restricted stock units vested and were reported as acquired, and 14,613 shares were disposed of at $1.58 per share, leaving 24,881 shares owned directly after the transactions. The filing also shows 223,430 restricted stock units/derivative securities beneficially owned following the reported transactions. The RSUs convert one-for-one to common stock and stem from grants of 118,483 RSUs on 09/30/2024 and 144,441 RSUs on 01/22/2025, each vesting in three equal annual installments beginning on the first anniversary of the respective grant dates.
Allarity Therapeutics, Inc. filed an S-3 shelf registration describing an offering that includes 760,916 shares of Common Stock and 801,584 Pre-Funded Warrants exercisable for Common Stock at an exercise price of $0.0001 per share. The company’s authorized capital structure includes 250,000,000 shares of Common Stock and 500,000 shares of undesignated preferred stock. The prospectus enumerates the distribution methods permitted under the plan, including ordinary brokerage transactions, block trades, principal purchases and exchange distributions. The document lists estimated offering expenses including $20,000 for accounting fees and $50,000 for legal fees. A table of exhibits identifies corporate charter amendments, bylaws, a specimen stock certificate, forms of pre-funded warrant, a securities purchase agreement and a registration rights agreement dated September 22, 2025. The filing is signed by the CEO, CFO and multiple directors with signatures dated September 25, 2025.
Allarity Therapeutics, Inc. filed a Form 8-K reporting a material event dated
Allarity Therapeutics, Inc. reported interim results showing constrained operations but sufficient near-term liquidity. The company recorded a net loss of $5.1 million for the six months ended June 30, 2025 and negative operating cash flow of $8.2 million over the same period. Management states that $17.8 million of cash, cash equivalents and restricted cash as of June 30, 2025 is estimated to be sufficient to fund operations for at least the next 12 months under the current plan. The company completed corporate actions including Reverse Stock Splits (retroactively applied) and repurchased 2,455,702 shares for $2,565,511, leaving $2,434,489 available under its repurchase program. A legal/contract liability to Novartis resulted in current liabilities recorded as $3.6 million accounts payable, $1.4 million convertible promissory notes and accrued interest, and $0.4 million accrued liabilities. The company settled a prior SEC investigation by paying a $2.5 million civil penalty which was paid in cash on April 2, 2025.
On 15 Jul 2025 Allarity Therapeutics, Inc. (NASDAQ: ALLR) filed a Form 8-K under Item 8.01 to disclose the execution of a new commercial agreement with an undisclosed EU-based biotechnology company. The filing states only that the agreement was announced via a press release furnished as Exhibit 99.1, which is incorporated by reference.
No financial terms, partner identity, milestones, or projected revenue were provided in the 8-K, and the company did not report any changes to financial statements, guidance, or capital structure. Other 8-K items were not triggered. Investors must review Exhibit 99.1 for substantive economic details before assessing materiality.
FAQ
What is the current stock price of Allarity (ALLR)?
What is the market cap of Allarity (ALLR)?
